Healinno Medical

Healinno Medical (智愈医疗) has emerged as a pioneer in waterjet surgical robotics, developing China’s first autonomous high-energy waterjet ablation system for urological applications. Founded in 2021 within Beijing’s Economic-Technological Development Area, the company focuses on intelligent surgical instruments that combine new energy delivery devices with robotic platforms.

Company Overview

Healinno Medical was established by Shi Yilun, a medical device industry veteran with over 20 years of experience in R&D and commercialization. The company positions itself as an intelligent surgical instrument developer rather than a conventional surgical robot company, emphasizing a dual-drive approach that integrates novel energy devices with robotic control systems.

The founding team includes professionals who previously worked at leading multinational medical device corporations. This experience informed their strategic focus on benign prostatic hyperplasia (BPH), a condition affecting millions of men in China and representing a significant unmet clinical need for thermal-free treatment options.

Healinno Medical has secured five funding rounds within its first three years of operation. The Pre-A++ round in May 2024, exceeding 60 million yuan, was led by Chengde Capital with participation from Legend Star. Existing investors Shunwei Capital, Lilly Asia Ventures (LAV), and Zhonghai Investment continued their support.

Core Products

metaFlow® Waterjet Surgical Robot

The metaFlow system represents China’s first autonomous high-energy waterjet surgical robot designed for BPH treatment. The platform accelerates saline solution to supersonic velocities, creating a cavitation effect capable of ablating prostatic tissue without thermal damage.

The system entered NMPA’s Innovative Medical Device Special Review Program (green channel) in December 2023. The first clinical trial surgery was performed at Beijing Hospital in January 2024 by Professor Liu Ming’s urology team. Multicenter registration clinical trials are currently underway across China.

metaBlade™ Disposable Waterjet Blade

metaBlade is a single-use waterjet surgical instrument designed as a consumable component for the metaFlow system. It also received green channel designation from NMPA in December 2023 alongside the main robotic platform.

Technology & Innovation

Healinno Medical has achieved breakthroughs in several core technologies through approximately four years of development:

The high-pressure plunger pump, traditionally a technological bottleneck in China with domestic products lagging behind international standards, was successfully developed through collaboration with leading domestic experts. This component enables the precise generation of high-energy waterjet streams required for tissue ablation.

The system’s ultrasound-guided imaging technology enables real-time surgical planning, automatically identifying and avoiding critical anatomical structures such as the verumontanum and ejaculatory ducts. This approach addresses limitations of traditional endoscopic visualization where surgeons can only see what the camera shows.

Four key technical innovations distinguish the platform: multi-dimensional imaging real-time planning, multi-axis coordinated automatic rotational cutting, high-energy thermal-free waterjet precise control, and multi-modal data global monitoring.

The company has filed 42 domestic patents as of 2024. In July 2024, Healinno Medical received the WIPO Global Award, becoming one of five Chinese SMEs to receive this recognition for intellectual property excellence.

Market Presence

Healinno Medical has established partnerships with multiple multinational medical device companies and maintains research collaborations with leading Chinese universities and top-tier hospitals.

The company’s technology addresses a specific market gap. While robot-assisted aquablation for BPH treatment has been validated by PROCEPT BioRobotics (NASDAQ: PRCT) in the US market, no domestic Chinese manufacturer previously offered this capability. Healinno Medical’s platform fills this void, potentially offering cost advantages through localized manufacturing and supply chain integration.

Clinical guideline recognition supports market potential. Robot-assisted high-energy waterjet resection is now recommended by the American Urological Association (AUA), European Association of Urology (EAU), and Chinese Urological Doctors Association (CUDA) guidelines.

Key Milestones

• 2021: Company founded in Beijing Economic-Technological Development Area
• 2023: metaFlow and metaBlade enter NMPA green channel (December)
• 2024: First clinical trial surgery completed at Beijing Hospital (January)
• 2024: Pre-A++ funding round exceeds 60 million yuan (May)
• 2024: Received WIPO Global Award (July)
• 2024: Named to KPMG Bio-Innovation Leading 50 list (April)
• 2025: Awarded Future Healthcare 100 Innovation Award (May)
• 2025: Presented prostate biopsy robot research at IROS 2025 (October)

Frequently Asked Questions

What products does Healinno Medical offer?

Healinno Medical’s core product is the metaFlow high-energy waterjet autonomous surgical robot, designed for treating benign prostatic hyperplasia. The system includes the metaBlade disposable waterjet blade as a consumable component. The company is also developing additional pipeline products including a prostate biopsy robot currently in research stages.

Is Healinno Medical publicly traded?

No, Healinno Medical is a privately held company. The company has completed five funding rounds from investors including Shunwei Capital, Lilly Asia Ventures, Chengde Capital, Legend Star, and Zhonghai Investment.

What is the regulatory status of Healinno Medical’s products?

The metaFlow waterjet surgical robot and metaBlade disposable blade entered NMPA’s Innovative Medical Device Special Review Program (green channel) in December 2023. The products are currently undergoing multicenter registration clinical trials in China. No CE Mark or FDA clearance has been obtained as of January 2026.